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PHARMACY NEWS
Pharmacy presentations on international platform - Federation of International Pharmaceutical 69th congress (Istanbul, Turkey)
This year, the 69th FIP international annual congress held in stunning and historically rich city Istanbul, Turkey from September 2009. The theme
of this year’s congress was Responsibility for Patient Outcomes – Are You Ready? Around 5000
pharmacists from different parts of the world attended this year’s congress. The congress offered many scientific and plenary sessions where
pharmacists shared their research, practices, innovations and local experiences in the area of
their expertise. It was a platform to teach and
learn reciprocally and exchange the ideas for the
amelioration of the profession across the globe.

A total of 11 abstracts were accepted this year in
the FIP congress from Department of Pharmacy
Services, AKUH. Four abstracts’ authors were
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chosen to present their research work on the
podium as oral presentations and seven abstracts
were presented as posters. Department of Pharmacy AKUH as well as Pakistan were represented by three participants, Mr Abdul Latif
Sheikh (Pharmacy Consultant AKUH), Mr Syed
Shamim Raza (Manager Pharmacy Services
AKUH) and Mr Muhammad Hammad (Clinical
Pharmacist AKUH).
Hospital Pharmacy Practice Symposium
A symposium was organised by the Society of
Hospital Pharmacist’s of Pakistan (SHPP) in collaboration with Riphah Institute of Pharmaceutical
Sciences in which the current role of the pharmacist in hospital pharmacy and future prospects
were presented by AKUH’s pharmacy staff. In the
symposium in addition to career counseling,
awareness of hospital pharmacy practice and its

scope in Pakistan were highlighted, The symposium included the presentation and interactive
sessions from the expert professionals in hospital pharmacy practice covering all the speciality
including drug distribution systems, pharmaceutical care concepts, specialised services, pharmacy practice research and role of the
pharmacist in an effective medication management system. The following presentation topics
were presented Future of Hospital Pharmacy:
Global Perspective and Basel Statement
Overview by Mr Abdul Latif Sheikh, President,
SHPP Consultant, Pharmacy Services, AKUH;
Pharmacist’s role in Medication Management
System by Ms Salwa Zubair, Assistant Manager,
Department of Pharmacy Services, AKUH.
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Summary of FDA Alerts 2009
Month

Drug(s)

Summary
FDA notified healthcare professionals of the risk of serious liver
injury, including liver failure and death, with the use of propylthiouracil in adult and paediatric patients. Physicians should
closely monitor patients on propylthiouracil therapy for symptoms and signs of liver injury, especially during the first six
months after initiation of therapy.

June

Propylthiouracil

June

Stimulant medications used in
children with attention-deficit/
hyperactivity disorder communication about an ongoing
safety review

June

Cefepime update of
ongoing safety review

Possible higher risk of death with cefepime, an antibiotic. FDA
has determined that the data do not indicate a higher rate of
death in cefepime-treated patients. Cefepime remains an appropriate therapy for its approved indications.

July

Immunosuppressant drugs:
required labeling changes

Certain immunosuppressant drugs to update their labeling to reflect that immunosuppressed patients are at increased risk for
opportunistic infections, such as activation of latent viral infections, including BK virus-associated nephropathy.

July

August

August

September

Varenicline and bupropion
(risk of serious neuropsychiatric
symptoms)

Leukotriene inhibitors

Potential risks of stimulant medications used to treat AttentionDeficit/Hyperactivity Disorder (ADHD) in children. There may be
an association between the use of stimulant medications and
sudden death in healthy children. The FDA is unable to conclude
that these data affect the overall risk and benefit profile of stimulant medications used to treat ADHD in children. FDA believes
that this study should not serve as a basis for parents to stop a
child’s stimulant medication. Any child who develops cardiovascular symptoms (such as chest pain, shortness of breath or
fainting) during stimulant medication treatment should immediately be seen by a doctor.

FDA notified healthcare professionals and patients that it has required the manufacturers of the smoking cessation aids varenicline and bupropion to add new Boxed Warnings and develop
patient Medication Guides highlighting the risk of serious neuropsychiatric symptoms in patients using these products. These
symptoms include changes in behaviour, hostility, agitation, depressed mood, suicidal thoughts and behaviour, and attempted
suicide. The added warnings are based on the continued review
of postmarketing adverse event reports for varenicline and
bupropion received by the FDA. These reports included those
with a temporal relationship between the use of varenicline or
bupropion and suicidal events and the occurrence of suicidal
ideation and suicidal behaviour in patients with no history of psychiatric disease.
FDA has requested that manufacturers of Leukotriene Inhibitors
(Monteleukast and others) include a precaution in the drug prescribing information (drug labeling) about the neuropsychiatric
events include postmarket cases of agitation, aggression, anxiousness, dream abnormalities and hallucinations, depression,
insomnia, irritability, restlessness, suicidal thinking and behaviour (including suicide), and tremor. FDA recommends that:
• Patients and healthcare professionals should be aware of the
potential for neuropsychiatric events with these medications.
• Patients should talk with their healthcare providers if these
events occur.
• Healthcare professionals should consider discontinuing these
medications if patients develop neuropsychiatric symptoms.

Mycophenolate mofetil (Cellcept)

FDA notified that cases of Pure Red Cell Aplasia (PRCA) have
been reported in patients treated with Mycophenolate. The
WARNINGS and ADVERSE REACTIONS sections of the Mycophenolate Prescribing Information have been revised to reflect
this new safety information. PRCA is a type of anaemia in which
there is a selective reduction of red blood cell precursors on
bone marrow examination. Patients with PRCA may present with
fatigue, lethargy, and/or abnormal paleness of the skin (pallor).
In some cases, PRCA was found to be reversible with dose reduction or cessation of therapy. In transplant patients, however,
reduced immunosuppression may place the graft at risk.

Promethazine hydrochloride
injection and severe tissue injury

A Boxed Warning is being added to the prescribing information
for Promethazine Hydrochloride products, describing the risks of
severe tissue injury, including gangrene, requiring amputation
following intravenous administration of promethazine. The
Boxed Warning will remind practitioners that due to the risks of
intravenous injection, the preferred route of administration is
deep intramuscular injection and that subcutaneous injection is
contraindicated.
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DRUG SAFETY UPDATE
Ceftriaxone interaction with calcium
FDA notified healthcare professionals of an
update to a previous alert that addresses the
interaction of ceftriaxone with calcium-containing products, based on previously reported fatal cases in neonates. Two in-vitro
studies were conducted to assess the potential for precipitation of ceftriaxone-calcium
when ceftriaxone and calcium-containing
products are mixed in vials and in infusion
lines. These two in vitro studies were conducted in neonatal and adult plasma to assess the potential for precipitation of
ceftriaxone-calcium using varying ceftriaxone
and calcium concentrations, including concentrations in excess of those achieved invivo. Based on the results of these studies,
FDA now recommends that ceftriaxone and
calcium-containing products may be used
concomitantly in patients older than 28 days
of age, using the precautionary recommendations noted because the risk of precipitation is
low in this population. FDA had previously
recommended, but no longer recommends,
that in all age groups ceftriaxone and calcium-containing products should not be administered within 48 hours of one another.
SWINE FLU UPDATE
In late March and early April 2009, an outbreak of H1N1 influenza A virus infection was
detected in Mexico, with subsequent cases
observed in many other countries including
the United State. On June 11, 2009, the
World Health Organization raised its pandemic alert level to the highest level, phase 6,
indicating widespread community transmission on at least two continents. Two classes
of antiviral drugs are available for the treatment and prevention of influenza : the neuraminidase inhibitors zanamivir and
oseltamivir, which are active against both influenza A and B. The adamantanes, amantadine and rimantadine, which are only active
against influenza A. The first preparations for
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pandemic H1N1 influenza vaccine became
available in the United States in early October
2009, though it will take time for adequate
supplies to be produced and distributed.
(Afsheen Zafar and Saba Saleem, Trainee
Pharmacists)
Acetaminophen after-shots may undermine
immune response in infants

According to a study published in the British
Medical Journal,The Lancet (2009), administration of acetaminophen after vaccines reduces their efficacy and also that of
subsequent booster doses. An RCT was conducted which included 459 healthy infants
and the research concluded that the effect of
acetaminophen has something to do with the
anti-inflammatory property of the drug; it interrupts the “early innate and adaptive responses” to the vaccine shots. It is still okay
to use acetaminophen to treat fever, but just
not recommended to prevent it. (Fasiha Abdulaziz, Trainee Pharmacist)
EUROPEAN MIGRAINE GUIDELINES
UPDATES
Zolmitriptan tablets and nasal spray and rizatriptan tablets were determined to be effective in children and adolescents.Topiramate is
recommended for prophylactic treatment of
chronic migraine. Botulinum toxin A is not considered effective in episodic migraine. For very severe migraine attacks, the guidelines recommend
intravenous acetylsalicylic acid or subcutaneous
sumatriptan as the drugs of first choice. Status
migrainosus, in which migraine lasts almost without interruption for more than 72 hours, "can be
treated by corticosteroids, although this is not universally held to be helpful, or dihydroergotamine,"
according to the recommendations. For migraine
prophylaxis, beta-blockers (propranolol and metoprolol), flunarizine, valproic acid, and topiramate
are the drugs of first choice.The guidelines also
include recommendations for specific situations,
such as emergencies, menstrual migraines, migraine in pregnancy, and migraine in children and
adolescents.

